Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (January 2022)
24 slides from Inspiremd's investor presentation, Jan 10, 2022
Slide 1: InspireMD
INSPIREM9
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: Investment Highlights
Investment Highlights MicroNet™ Proprietary Platform Technology Highly differentiated profile for treatment of carotid artery disease and stroke prevention clinicians Evidenced based / Clinically Supported CGuard™ EPS 8 clinical trials completed with >1,600 patient procedures and 3 ongoing clinical
Slide 4: Our Leadership
Our Leadership Marvin L. Slosman President and CEO @ Cordis. INSPIREM9D I Craig Shore Andrea Chief Financial Officer P Glob: Bristal-Myers Squib Boston, Scientific ‘SS UNIVERSITAT if! BARCELONA a ese
Slide 5: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE —— eo ——— AWAITING CONVERSION TO ENDO 30% Surgical 23% Surgical? 35% Surgical? 19% Surgical* 58% Surgical> \ \
Slide 6: Stroke is the Second Biggest Cause of Death Globally
Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually? p Two Causes of Death Globally (20: + 5 million deaths each year? 10 2 * 5 million people left permanently disabled* 8 * $46 billion associated with stroke management in the US alone? * 8
Slide 7: THE PROBLEM: Risks with Existing Approaches to CAD
THE PROBLEM: Risks with Existing Approaches to CAD Conventional approaches come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Risk of complications: Risk of complications: Myocardial infarction risk! (heart attack) Procedural and Cranial nerve injury risk2 (vertigo, hearing l
Slide 8: THE PROBLEM: Risk of Embolization with Conventional CAS
THE PROBLEM: Risk of ‘Boisiistn iene Conventional CAS MRI revea t-procedural ce al embol Post-Procedure Pre-Procedure 90% occlusion of — MRI of a pre-existing white Successful MRI reveals new multiple micro-infarcts the carotid artery _ matter infarction (obstruction) opening of the (obstructions) d
Slide 9: Mechanics Translate to Clinical Results
Mechanics Translate to Clinical Results Pore size is an important differentiating factor in stent selection 4ST GEN Open Cell Stent 2N° GEN Closed Stent YG WIRES 451 GEN Closed _ Cell Stent 3" GEN Closed Stent Ss = CGuards’s Pore size opening is ~1/12 or 8.5% that of a conventional open cell stent I
Slide 10: OUR SOLUTION: Proprietary MicroNet Technology
OUR SOLUTION: Proprietary MicroNet™ Technology ~~ ‘it ) r ) > X& f % Pr sgl plaque/t jus a vajebetween struts Conventional Open Cell Stent (15t GEN): Bare or dual layer approach, with plaque protrusion risk An Embolic Prevention System (EPS) for Ultimate Thrombus Protection MicroNet captures and loc
Slide 11: Carotid Solution: Our Well Studied Mesh-Covered Technology
Carotid Solution: Our Well Studied Mesh-Covered Technology More than patients in Clinical Publications & Studies INSPIREMD
Slide 12: Timeline Growth: From Alternative Stent to Potential New Gold Standard
Timeline Growth: From Alternative Stent to Potential New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS RD'S STANDING (known & anticipated) 2015 _| CARENET Safety, Efficacy & Neuroprotection over other stents data owes 4 2016 | PARADIGM All comers population; Excellent clinical results (o) se EIS E
Slide 13: Clinical Support Highlights / Call out
Clinical Support Highlights / Call out 2015-2021 CARENET Trial First in Man Study- Demonstrated Safety, Efficacy, & Neuroprotection over other stents data INSPIREMD PARADIGM Opened CARENET study inclusion criteria and concluded the safety and clinical outcomes were applicable to others outside of hi
Slide 14: CGuard EPS Yields Superior Clinical Outcomes
CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard trends Superior (Minor stroke in 21/1,635 patients in 8 studies 6.00% : (1.28%) 5.20% ° aibths 4.50% e . 5 * CGuard has a superior profile vs. historical weed 5 data on both conventional ca
Slide 15: Potential Multi Billion Dollar Market Opportunity
Potential Multi Billion Dollar Market Opportunity Our MicroNet™ covered stents like CGuard™ could become the new gold standard WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with CGuard™ ® Current addressable market: > $666 million
Slide 16: Commercial Footprint
Commercial Footprint Signed agreement with Chinese distributor. Working toward distribution U.S. Market Investigation Device Exemption (IDE) approval September 2020; US trial initiated Q3 2021 Exploring expansion opportunities Taiwan, Japan, and Korea BD current Markets GB reeistration work Underway
Slide 17: Growth Pathway to the U.S. Market
Growth Pathway to the U.S. Market U.S. Market Opportunity* Size: 155K High Grade Carotid Artery Stenosis (HGCS) interventions estimated in 2021 Opportunity: At a price of $1,650 per stent, the addressable market is estimated to be approximately $317 million Executing and Funded Approval of FDA Prema
Slide 18: Our Lead Product, CGuard
Our Lead Product, CGuard™ Pre- and Post-Procedure with CGuard 26,000+° Total protected stents sold to date with excellent clinical results * As of September 30, 2021 INSPIREM9D
Slide 19: InspireMD Pipeline
InspireMD Pipeline Clinical Commercial Stage Brain Protection: CGuard™ EPS Carotid Stent System New CGuard Prime Delivery System Trans Carotid CAS: New SwitchGuard Accessory Device New Short Shaft CGuard Peripheral Indications: PGuard™ EPS - Nero Protection / Acute Stroke Indication: NGuard™ EPS INS
Slide 20: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Our Key Value Drivers and Strategic Pathways + USA regulatory approval = Guard bameitaunéti + China regulatory advancement : : + Neuro Guard launch + Asia Expansion + Commercial growth + Chinese trial enrollment + Uplisting to NASDAQ + USA reimbursement initiativ
Slide 21: Our Robust Intellectual Property Portfolio
Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP USA 16 1 6 Rest of World 37 1 6 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products INSPIREM9D
Slide 22: Summary Financials
Summary Financials January 7, 2022 NASDAQ Capital Markets NSPR Stock Price $2.94 Average 3 Month Volume 0.224M Shares Outstanding 8.3M Market Capitalization $24.4M Cash Balance - December 315t, 2021* $34.0M Debt $0M * The Company is providing its estimated unaudited cash balance as of December 31, 2
Slide 23: Our Board of Directors
Our Board of Directors Marvin L. Slosman President and CEO Paul Stuka Chairman Michael Berman Director Campbell Rogers, M.D. Director Thomas Kester Director Gary Roubin, M.D.,Ph.D. Director Katie Arnold Director INSPIREMD Mr. Slosman has over 30 years of experience in the medical device industry wit
Slide 24: InspireMD
INSPIREM9 NASDAQ = NSPR